argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
May 2, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today an...
GSK Gears Up for Q1 Earnings: Here's What to Expect
We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.
Why Argenx's (ARGX) Stock Price Moved Up 11% on Thursday
Argenx (ARGX) surges after a Japanese rival posted disappointing results from a late-stage study on its investigational drug for generalized myasthenia gravis.
Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?
Argenx (ARGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength ...
Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
Biotech stocks Argenx and Immunovant surged Thursday — and Tourmaline fell — on a rival's lackluster muscle disease drug study.
Is a Surprise Coming for argenx (ARGX) This Earnings Season?
argenx (ARGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024
February 22, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, to...
3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition
Now that the FED is looking to lower interest rates this year, cheaper money and more accessible financing will let investors venture into riskier places in the economy and the stock market. While ...
5 medical stocks growing earnings by triple digits
While most of the market focuses on hyper-growth technology stocks rewarded by Wall Street as long as they mention the word "artificial intelligence" in their earnings calls, the reality is that th...
argenx: Upgrading To 'Strong Buy' On Vyvgart's Q4 Sales, Empasiprubart Data, Pipeline Expansion
Vyvgart generated $1.2 billion in net sales in 2023 and is in a good position to continue performing well in 2024 and beyond. Empasiprubart has generated strong results in the first cohort of MMN p...
How Argenx (ARGX) Stock Stands Out in a Strong Industry
Argenx (ARGX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that...
argenx (ARGX) Tanks on Top-Line Data From Pemphigus Study
argenx's (ARGX) phase III ADDRESS study, evaluating efgartigimod subcutaneous for treating pemphigus, fails to meet primary and secondary endpoints. Stock falls.
Immunovant Scores Much-Needed Win Following Argenx-Led Sell-off
Immunovant unveiled promising results for a Graves' disease treatment on Thursday, helping IMVT stock reverse a recent downfall.
Related Companies